Editor's note

This ExpertREACT article was originally published on 24 February 2012. Financial results and market positions described reflect the state of knowledge at that date.

Industry sales essentially flat at $20.8bn

According to VacZine Analytics' calculations, the top five vaccine players reported approximately $20.8bn in vaccine sales in 2011, compared with nearly $22bn in 2010. The pandemic influenza vaccines that had contributed approximately $3.5bn in 2010 had effectively disappeared from reported revenues, with GSK, Sanofi Pasteur and Novartis Vaccines all showing declines in dollar terms. Government austerity programmes - particularly across Europe - created additional pricing pressure on established vaccine franchises. Sales in reported currency terms were also subject to variation due to an appreciating US dollar versus Sterling and Euro.

GSK Biologicals led in dollar terms with $5.63bn in 2011 revenues. Its bivalent HPV vaccine Cervarix recorded a remarkable £506m - more than double 2010 revenues of £242m - largely driven by a one-time catch-up programme of five cohorts under Japan's national HPV immunisation programme. GSK stated that Cervarix EU tenders were, however, under pricing pressure. In other GSK news, a positive CHMP opinion had been received in Europe for Nimenrix, its conjugate meningococcal ACWY vaccine. Sanofi Pasteur recorded €3,469m in full year sales, with the pandemic comparison year particularly affecting reported growth.

GSK Cervarix 2011 revenues
£506m
More than double 2010 revenues of £242m, driven by Japan's national HPV catch-up immunisation programme

New vaccines needed as growth catalysts

VacZine Analytics argued that only genuinely new vaccines - principally dengue and a broad-coverage meningococcal B vaccine - had the potential to deliver the industry's next phase of meaningful revenue growth. Incremental lifecycle management and geographic expansion into emerging markets would contribute, but were insufficient to replicate the step-change revenues seen during the H1N1 pandemic or from earlier blockbuster launches like Prevnar and Gardasil. The industry was described as being in a holding pattern, managing existing franchises while awaiting critical regulatory outcomes for MenB and the completion of large Sanofi dengue Phase III trials.